MARKET WIREYahoo! Finance Canada • 18h ago
Pulse Biosciences, Inc. (PLSE) Stock Price, News, Quote & HistoryYahoo! Finance Canada report covering Pulse Biosciences Inc (PLSE) market action, institutional positioning, and fundamental catalysts.
Why PLSE Stock dropped -5.84% Today — RQD Quant Desk Flash
$52.24 -5.84% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $51.59
Pulse Biosciences Inc (PLSE) carries a Roarable Rating of D- (Sell) with 39/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D- • RED ALERT
Cap $3.73B
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on PLSE Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is PLSE stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, Pulse Biosciences Inc (NASDAQ: PLSE) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 39/100 at a spot price of $52.24 (-5.84% 1D, market cap $3.73B). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 14/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, PLSE ranks #480 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does PLSE compare to NVST and IRTC in the Health Care sector?
▼
Within the Health Care sector (Medical/Dental Instruments), PLSE carries a Roarable D- (39/100 RQD), trailing P/E of N/A, gross margin of -30.0%, and ROIC of -30.7%. By comparison, NVST (Envista Holdings Corporation) holds a D grade (46/100 RQD, P/E 84.1x, ROIC 5.1%, cap $3.78B) and IRTC (iRhythm Holdings Inc.) posts a D grade (47/100 RQD, P/E N/A, ROIC -13.5%, cap $4.07B). Among the 5-stock peer group, NVST leads on earnings multiple (84.1x) while NVST leads on capital efficiency (5.1% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for PLSE?
▼
Per PLSE's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001625101), Pulse Biosciences Inc generated $350.0K in revenue, -$72.8M in net income, and -$54.4M in free cash flow against $94.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $51.59 (-1.24%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (39/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.6% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • D-
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw D- · Rk D-
Each axis scored 0–20
12M PRICE TARGET CONE-8.6% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for PLSE)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (39/100 Composite)
🔍 WHY PLSE SCORES 39/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+14/20 pts (36% of score)
20D Institutional Volume Accumulation (±12.5% realized swing band)
▲ #2 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (21% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade E$48.54+4.7% Next Q
31
Q2 (-2Q)Grade E$50.84+4.6% Next Q
34
Q3 (-1Q)Grade E$53.20-1.8% Next Q
36
CurrentGrade D-$52.24-7.6% Hist 90D α
39
Trajectory: E (31) → D- (39)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a PLSE Turnaround Squeeze
While PLSE currently carries a cautious 39/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($51.24) and Max Pain ($54.85) forces dealer call-delta covering toward $61.84.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $PLSE• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “PLSE Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why PLSE Stock dropped -5.84% Today — RQD Quant Desk Flash
Pulse Biosciences Inc (PLSE) dropped -5.84% to $52.24, trading at 86% of its 52-week range ($12.56 – $58.9). Stretched risk/reward at current multiples (-31% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 86% of its 52-week range ($12.56 – $58.9) with RSI-14 at 51.9 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $52.24 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D- (Sell) backed by 0% gross margin and $0 annual free cash flow.
Live PLSE Headlines & Catalysts
CATALYSTInvesting.com • 21h ago
Canaccord raises Pulse Biosciences stock price target on tech potentialInvesting.com report covering Pulse Biosciences Inc (PLSE) market action, institutional positioning, and fundamental catalysts.
MARKET WIRETradingView • 1d ago
Pulse Biosciences, Inc Estimates – NASDAQ:PLSETradingView report covering Pulse Biosciences Inc (PLSE) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo Finance • 1d ago
Pulse Biosciences (PLSE) Stock Fair Value Rises After Analyst Target IncreasesYahoo Finance report covering Pulse Biosciences Inc (PLSE) market action, institutional positioning, and fundamental catalysts.
MARKET WIREBusiness Wire • 1d ago
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business Wire report covering Pulse Biosciences Inc (PLSE) market action, institutional positioning, and fundamental catalysts.
CATALYSTSimply Wall St • 1d ago
Is Pulse Biosciences (PLSE) Fully Priced As Clayman Partnership Builds Commercial And Clinical Traction?Simply Wall St report covering Pulse Biosciences Inc (PLSE) market action, institutional positioning, and fundamental catalysts.
CATALYSTYahoo Finance • 1d ago
Pulse Biosciences (PLSE) Stock Still Seems Rich Against Book ValueYahoo Finance report covering Pulse Biosciences Inc (PLSE) market action, institutional positioning, and fundamental catalysts.
MARKET WIREhttps://www.siam.in/ • 1d ago
Pulse Biosciences (PLSE) Edges Higher to $52.95 as Buyers Defend Key Support - IV Crush Alerthttps://www.siam.in/ report covering Pulse Biosciences Inc (PLSE) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo • 4d ago
DexCom (DXCM) Surpasses Q3 Earnings and Revenue EstimatesDexCom (DXCM) delivered earnings and revenue surprises of +10.61% and +1.64%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
MARKET WIREYahoo • 4d ago
Pulse Biosciences to Present at Stifel 2026 Healthcare ConferenceHAYWARD, Calif., October 29, 2026--Pulse Biosciences, Inc. (Nasdaq: PLSE), the company leveraging its ever evolving novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring PLSE)
- ✓Walkthrough of PLSE's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
PLSE // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +160.81%▲ ASCENDING CHANNEL
2026-11-03O $55.48H $55.48L $52.24C $52.24VOL 466.5K
RES: $76.85SUP: $46.66SMA50: $51.24SMA200: $31.75
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
PLSE Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on PLSE today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for PLSE. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for PLSE today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PLSE)
Health Care Rank #480 of 1016
⚔️ NVST vs PLSE Full Matrix →
1. Head-to-Head Health Care Peer Comparison (PLSE vs. NVST, IRTC, ICUI, ATRC)
Industry: Medical/Dental Instruments (120 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Pulse Biosciences Inc (PLSE) ranks #480 by composite RQD confidence (39/100, grade D-) and #187 by equity capitalization ($3.73B). Within this direct 5-issuer industry benchmark cohort, NVST leads on earnings valuation at 84.1x trailing P/E, while NVST leads on capital efficiency and profitability with 5.1% ROIC and 54.7% gross margin. ATRC currently holds the highest overall quantitative score in the immediate peer group at 63/100 (C) compared with PLSE at 39/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| PLSE
ACTIVE
Pulse Biosciences Inc | D- | 39/100 | — | -30.0% | -30.7% | -5.84% | $3.73B | Benchmark Subject |
| NVST Envista Holdings Corporation | D | 46/100 | 84.1x | 54.7% | 5.1% | -4.47% | $3.78B | /nvst-vs-plse → |
| IRTC iRhythm Holdings Inc. | D | 47/100 | — | 70.6% | -13.5% | -3.47% | $4.07B | /irtc-vs-plse → |
| ICUI ICU Medical Inc. | D+ | 56/100 | — | 36.8% | 1.0% | -2.89% | $4.10B | /icui-vs-plse → |
| ATRC AtriCure Inc. | C | 63/100 | — | 75.0% | -1.9% | -1.97% | $3.12B | /atrc-vs-plse → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001625101In its most recent audited fiscal period (FY2025, filed 2025-12-31), Pulse Biosciences Inc (PLSE) reported GAAP revenue of $350.0K (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$72.8M, operating cash flow of -$54.1M, and free cash flow of -$54.4M (-49.3% YoY). On the balance sheet, PLSE closed FY2025 with $94.5M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $350.0K | -$72.8M | -$54.1M | -$54.4M | $94.5M | — |
| FY2024 (FY) | 2024-12-31 | $0 | -$53.6M | -$36.3M | -$36.5M | $132.5M | — |
| FY2023 (FY) | 2023-12-31 | $0 | -$42.2M | -$33.0M | -$33.0M | — | — |
3. PLSE Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs PLSE stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, Pulse Biosciences Inc (NASDAQ: PLSE) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 39/100 at a spot price of $52.24 (-5.84% 1D, market cap $3.73B). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 14/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, PLSE ranks #480 in composite RQD confidence.
How does PLSE compare to NVST and IRTC in the Health Care sector?
Within the Health Care sector (Medical/Dental Instruments), PLSE carries a Roarable D- (39/100 RQD), trailing P/E of N/A, gross margin of -30.0%, and ROIC of -30.7%. By comparison, NVST (Envista Holdings Corporation) holds a D grade (46/100 RQD, P/E 84.1x, ROIC 5.1%, cap $3.78B) and IRTC (iRhythm Holdings Inc.) posts a D grade (47/100 RQD, P/E N/A, ROIC -13.5%, cap $4.07B). Among the 5-stock peer group, NVST leads on earnings multiple (84.1x) while NVST leads on capital efficiency (5.1% ROIC).
What are the biggest fundamental strengths and SEC risk factors for PLSE?
Per PLSE's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001625101), Pulse Biosciences Inc generated $350.0K in revenue, -$72.8M in net income, and -$54.4M in free cash flow against $94.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is PLSE trading relative to its 50-day, 200-day, and 52-week technical levels?
PLSE last traded at $52.24 (-5.84% on volume of 466,482 shares), positioning the stock +1.95% above its 50-day simple moving average ($51.24) and +64.54% above its 200-day simple moving average ($31.75). Across its 52-week range of $12.56 to $58.90, PLSE sits at the 85.6% percentile with a 14-day RSI of 51.9 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($45.71 to $58.77).
PLSE Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is PLSE stock moving today?
Why PLSE Stock dropped -5.84% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-31% return on capital) under elevated 10-year interest-rate pressure.
ROARABLE RATING BRIEF • RQD 39/100 (D-)
✓ STAGE-C NUMBER FIREWALL VERIFIED
PLSE — Pulse Biosciences Inc: What the Facts Mean to a Prospective Investor
Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:22:36Z
Roarable Rating Brief: What This Means to a Prospective Investor
The Roarable RQD Score is 41 / D-, labeled "Roarable Sell — Vulnerable Balance Sheet & Flow," per the Roarable RQD rating. Across its five pillars:
- Fundamental Cash Engine (6 / 20): Per the Roarable RQD rating, ROIC is -30.7% and FCF yield is -1.38%. This is the weakest-scoring pillar and indicates the business is not currently generating cash returns on invested capital. For a prospective investor, the valuation case rests on future cash generation that the reported history does not yet show.
- Whale / 13F Flow (16 / 20): Per the Roarable RQD rating, this pillar reflects institutional accumulation and options positioning. It is the strongest pillar, suggesting institutional interest is a meaningful support factor, though the source data does not itemize the 13F holdings.
- Insider Conviction (3 / 20): Per the Roarable RQD rating, this reflects SEC Form 4 and Congressional PTR cluster flow. The low score signals weak insider-side confirmation of the thesis.
- Macro Regime Fit (8 / 20): Per the Roarable RQD rating, beta is 1.0 with sector sensitivity noted. The stock moves in line with the market, offering no defensive cushion.
- Forensic Balance Sheet (8 / 20): Per the Roarable RQD rating, Altman Z is 2.5, Piotroski F is 2/9, and Debt/Equity is 0.5. These are mixed-to-weak readings that point to limited financial resilience.
Investor implication: the upside case depends on the stock's momentum and institutional support outrunning weak cash generation and a modest balance sheet. Valuation tradeoffs are significant because standard earnings multiples are not available in the source data. This analysis is educational and not personalized financial advice.
Business
Pulse Biosciences Inc (PLSE) is a NASDAQ-listed issuer in the Health Care sector, Medical/Dental Instruments industry, per the company profile. The source data does not describe its specific products, customers, or revenue model beyond reported revenue of $0.3M for FY 2025 per the SEC financials. Its sector and industry classification places it within medical instrument manufacturing.
Financial Trend
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $0.3M | $-76.9M | $-72.8M | N/A | $-54.4M | $80.7M | N/A |
| FY 2024 | $0.0M | $-56.3M | $-53.6M | N/A | $-36.5M | $118.0M | N/A |
| FY 2023 | $0.0M | $-43.6M | $-42.2M | N/A | $-33.0M | N/A | N/A |
Per the SEC financials, the company has reported losses in each period, with operating losses widening from $-43.6M (FY 2023) to $-76.9M (FY 2025). Per the market data, gross margin is -30%, operating margin is -60%, and net margin is -60%. ROIC is -30.7%. Per the Roarable RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 2/9. Cash declined from $118.0M (FY 2024) to $80.7M (FY 2025), and debt is reported as N/A in the source data.
Recent Catalysts & News Wire Analysis
- Canaccord price target raise: Per the news wire, Canaccord raised its price target on the tech potential, categorized as a green-light item tagged CATALYST.
- Fair value / analyst target increases: Per the news wire, a Yahoo Finance report covers fair value rising after analyst target increases (yellow, MARKET WIRE).
- Clayman partnership: Per the news wire, a Simply Wall St piece asks whether the stock is fully priced as the Clayman partnership builds commercial and clinical traction (green, CATALYST).
- Inducement grants: Per the news wire, Business Wire reports inducement grants under Nasdaq Listing Rule 5635(c)(4) (yellow, MARKET WIRE).
- Watch item: Several items are general market-wire coverage without specific fundamental detail.
Per the Butterfly Supply-Chain Graph, supply chain is NONE, with no butterfly links and no proprietary signals.
Open Questions
- What are the company's specific products, customers, and revenue drivers, given that FY 2025 revenue is only $0.3M?
- What is the total debt position, since debt is reported as N/A across all periods?
- What is the path to positive free cash flow, given FCF of $-54.4M in FY 2025?
- What are the terms and milestones of the Clayman partnership referenced in the news wire?
- What is the institutional and 13F holder breakdown behind the 16 / 20 whale-flow pillar?
PLSE Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Pulse Biosciences Inc (PLSE) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Yahoo! Finance Canada • 18h ago
Pulse Biosciences, Inc. (PLSE) Stock Price, News, Quote & History Yahoo! Finance Canada report covering Pulse Biosciences Inc (PLSE) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST Investing.com • 21h ago
Canaccord raises Pulse Biosciences stock price target on tech potential Investing.com report covering Pulse Biosciences Inc (PLSE) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE TradingView • 1d ago
Pulse Biosciences, Inc Estimates – NASDAQ:PLSE TradingView report covering Pulse Biosciences Inc (PLSE) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance • 1d ago
Pulse Biosciences (PLSE) Stock Fair Value Rises After Analyst Target Increases Yahoo Finance report covering Pulse Biosciences Inc (PLSE) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Business Wire • 1d ago
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire report covering Pulse Biosciences Inc (PLSE) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST Simply Wall St • 1d ago
Is Pulse Biosciences (PLSE) Fully Priced As Clayman Partnership Builds Commercial And Clinical Traction? Simply Wall St report covering Pulse Biosciences Inc (PLSE) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST Yahoo Finance • 1d ago
Pulse Biosciences (PLSE) Stock Still Seems Rich Against Book Value Yahoo Finance report covering Pulse Biosciences Inc (PLSE) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE https://www.siam.in/ • 1d ago
Pulse Biosciences (PLSE) Edges Higher to $52.95 as Buyers Defend Key Support - IV Crush Alert https://www.siam.in/ report covering Pulse Biosciences Inc (PLSE) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
PLSE Bull vs. Bear Conversation Board — What's Your Call at $52.24?
🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON PLSE 🐻 67% BEARISH CONVICTION
RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH
🎯 Target: $48.82 (-12.0%)
📌 Pinned Debate 🔥 Official Bull vs. Bear Debate: Is PLSE (D- • RQD 41/100) a Buy at $55.48?
Welcome to the PLSE (Pulse Biosciences Inc) Roar Pit. Current RQD Composite is 41/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Medical/Dental Instruments. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
MU MultipleCompression Forensic Accounting Watch 🐻 BEARISH
🎯 Target: $42.16 (-24.0%)
Spot @ $55.48 Pump the brakes on PLSE — check the valuation vs. margin headwinds
Everyone in here is repeating the bull case on PLSE, but look at what you are paying: current EV/EBITDA multiples with -30.0% gross margins. Unless Pulse Biosciences Inc expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
TA TapeReader_Pro Verified K Arena Trader 🐂 BULLISH
🎯 Target: $67.69 (+22.0%)
Spot @ $55.48 PLSE cash flow & RQD setup is being underpriced by the Street here
Looking at the 5-pillar RQD breakdown on PLSE, the market is fixating on short-term headline noise in Medical/Dental Instruments and ignoring the balance sheet and cash flow trajectory. At $55.48 (52-wk range $12.56 - $58.90), any beat on forward guidance forces shorts and underweight funds to chase.